Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT.
Alloreactivity of natural killer (NK) cells contributes to the GVL reaction after allogeneic hematopoietic SCT (allo-HSCT). However, various procedure-related factors may affect NK cell maturation and their ability to recognize and kill leukemic cells. In this study, we prospectively evaluated expression of NK cell inhibitory receptors in 83 adults treated with myeloablative, killer cell Ig-like receptor (KIR)-ligand-matched allo-HSCT. NK cell maturation was evaluated by comparing the phenotypic patterns after allo-HSCT with the donor ones. The frequencies of KIR3DL1 were comparable to the donor ones on day +28, while they decreased significantly starting from day +100. The expression of KIR2DL2/3 was significantly lower in patients compared with donors up to day +100. The expression of KIR2DL1, despite continues growth, remained significantly decreased for 1 year after allo-HSCT. NKG2A was over-expressed up to day +180. Within 1 year after allo-HSCT, the NK cell phenotypic pattern tended to recapitulate the donor type. The process was disturbed by the use of steroids with significant differences observed on days +56 (P=0.01) and +100 (P=0.04). Up to day +100, reconstitution of NK cell receptor repertoire correlated with the absolute numbers of circulating CD3(+), CD3(+)CD4(+) and CD3(+)CD8(+) cells. Our observations should be taken into account when trying to predict potential benefit from NK cell alloreactivity.
Giebel
S
S
Department of Clinical and Experimental Oncology, Division of Bone Marrow Transplantation and Lymphoma, Comprehensive Cancer Centre, Maria Sklodowska-Curie Memorial Institute-Gliwice Branch, Gliwice, Poland. sgiebel@io.gliwice.pl
Dziaczkowska
J
J
Czerw
T
T
Wojnar
J
J
Krawczyk-Kulis
M
M
Nowak
I
I
Holowiecka
A
A
Segatti
A
A
Kyrcz-Krzemien
S
S
Kusnierczyk
P
P
Holowiecki
J
J
D000293:Adolescent; D000328:Adult; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology*; D007694:Killer Cells, Natural / Q000166:cytology*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D011446:Prospective Studies; D054340:Receptors, KIR / Q000032:analysis*; D054342:Receptors, KIR2DL1 / Q000032:analysis; D054343:Receptors, KIR2DL2 / Q000032:analysis; D054344:Receptors, KIR2DL3 / Q000032:analysis; D054341:Receptors, KIR3DL1 / Q000032:analysis; D055607:Receptors, Natural Killer Cell / Q000032:analysis; D012038:Regeneration; D013256:Steroids / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D055815:Young Adult
C093100:KIR2DL1 protein, human; C515077:KIR2DL2 protein, human; C515078:KIR2DL3 protein, human; C515083:KIR3DL1 protein, human; D019653:Myeloablative Agonists; D054340:Receptors, KIR; D054342:Receptors, KIR2DL1; D054343:Receptors, KIR2DL2; D054344:Receptors, KIR2DL3; D054341:Receptors, KIR3DL1; D055607:Receptors, Natural Killer Cell; D013256:Steroids